TY - JOUR
T1 - Pharmacotherapy for unresectable metastatic colorectal cancer
AU - Rogers, Jane E.
AU - Dasari, Arvind
N1 - Funding Information:
This manuscript has not been funded.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Introduction: Unresectable metastatic colorectal cancer (mCRC) has a poor prognosis. Emerging treatment paradigms have improved outcomes in selected unresectable mCRC cases. Recent therapeutic advancements are due in part to a shift in trial designs. By examining CRC as a heterogeneous group of various tumor subtypes, researchers have identified molecular distinctions that have led to promising targets. Areas covered: Nineteen antineoplastic agents are included in the National Comprehensive Cancer Network guidelines for the palliative management of mCRC. However, not all patients will be candidates for each agent. New therapies for rare mCRC subtypes have emerged. Herein, the authors review these rare mCRC subtypes: microsatellite instability-high/deficient mismatch repair, BRAFV600E-mutant, and human epidermal growth factor receptor 2-positive tumors. Additionally, they provide an overview of unresectable mCRC management and future directions. Expert opinion: Treatment in the majority of mCRC patients (RAS wild-type or RAS-mutant, microsatellite instability-stable or -low/mismatch repair-proficient, BRAFV600E wild-type, or HER2-negative) needs further advancement and remains an unmet need. The authors believe that the key to identifying more breakthroughs in these mCRC patients is to continue to differentiate their tumors molecularly and clinically.
AB - Introduction: Unresectable metastatic colorectal cancer (mCRC) has a poor prognosis. Emerging treatment paradigms have improved outcomes in selected unresectable mCRC cases. Recent therapeutic advancements are due in part to a shift in trial designs. By examining CRC as a heterogeneous group of various tumor subtypes, researchers have identified molecular distinctions that have led to promising targets. Areas covered: Nineteen antineoplastic agents are included in the National Comprehensive Cancer Network guidelines for the palliative management of mCRC. However, not all patients will be candidates for each agent. New therapies for rare mCRC subtypes have emerged. Herein, the authors review these rare mCRC subtypes: microsatellite instability-high/deficient mismatch repair, BRAFV600E-mutant, and human epidermal growth factor receptor 2-positive tumors. Additionally, they provide an overview of unresectable mCRC management and future directions. Expert opinion: Treatment in the majority of mCRC patients (RAS wild-type or RAS-mutant, microsatellite instability-stable or -low/mismatch repair-proficient, BRAFV600E wild-type, or HER2-negative) needs further advancement and remains an unmet need. The authors believe that the key to identifying more breakthroughs in these mCRC patients is to continue to differentiate their tumors molecularly and clinically.
KW - Agents
KW - BRAFV600E mutant
KW - antineoplastic
KW - checkpoint inhibitors
KW - colorectal neoplasms
KW - human epidermal growth factor receptor 2
KW - microsatellite instability-high/deficient mismatch repair
UR - http://www.scopus.com/inward/record.url?scp=85123371457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123371457&partnerID=8YFLogxK
U2 - 10.1080/14656566.2021.1982895
DO - 10.1080/14656566.2021.1982895
M3 - Review article
C2 - 34534031
AN - SCOPUS:85123371457
SN - 1465-6566
VL - 23
SP - 211
EP - 220
JO - Expert opinion on pharmacotherapy
JF - Expert opinion on pharmacotherapy
IS - 2
ER -